Keyphrases
Finasteride
100%
Benign Prostatic Hyperplasia
100%
Prostatic Volume
83%
Prostate
66%
Urinary Symptoms
66%
Androgens
50%
Symptom Score
50%
Enlargement
50%
Dihydrotestosterone
50%
Urinary Flow Rate
50%
Prostatic Hyperplasia
50%
Placebo
33%
Prostate Gland
33%
Reductase
33%
Urinary Obstruction
33%
Urinary Flow
33%
Adverse Effects
16%
Placebo Groups
16%
Active Form
16%
High Incidence
16%
Two-dose
16%
Medical Therapy
16%
Prostate-specific Antigen
16%
Serum Concentration
16%
Treatment Duration
16%
Puberty
16%
Surgical Resection
16%
Ejaculatory Dysfunction
16%
Sexual Dysfunction
16%
Testosterone
16%
Once-daily
16%
Androgen-independent
16%
Decreased Libido
16%
Impotence
16%
Androgen Deprivation Therapy
16%
Volume Concentration
16%
Urethral Obstruction
16%
Aging Men
16%
Medicine and Dentistry
Pilus
100%
Urinary System
100%
Prostate Hypertrophy
100%
Androgen
71%
Placebo
42%
Androstanolone
42%
Urine Flow Rate
42%
Oxidoreductase
28%
Urinary Tract Obstruction
28%
Prostate Specific Antigen
14%
Combination Therapy
14%
Libido Disorder
14%
Obstruction
14%
N [bis(1 Aziridinyl)phosphinyl] 4 Iodobenzamide
14%
Target Tissue
14%
Urethra Obstruction
14%
Ejaculatory Disorder
14%
Surgery
14%
Diseases
14%
Adverse Effect
14%
Pharmacology, Toxicology and Pharmaceutical Science
Finasteride
100%
Prostate Hypertrophy
100%
Androgen
83%
Placebo
50%
Androstanolone
50%
Oxidoreductase
33%
Urinary Tract Obstruction
33%
Combination Therapy
16%
Prostate Specific Antigen
16%
N [bis(1 Aziridinyl)phosphinyl] 4 Iodobenzamide
16%
Libido Disorder
16%
Obstruction
16%
Urethra Obstruction
16%
Diseases
16%